We are advising Roche on the transaction

Davis Polk is advising Roche on its $750 million acquisition of PathAI, with up to $300 million in additional milestone payments. Following the transaction, Roche will integrate PathAI into its Diagnostics division. The transaction is expected to close in the second half of 2026, subject to customary closing conditions, including antitrust and regulatory approvals.

Founded in Basel, Switzerland in 1896, Roche is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.PathAI is a digital pathology and AI-powered technology company for pathology laboratories and the biopharmaceuticals industry.

The Davis Polk corporate team includes partner Marc O. Williams, counsel Jack Gordge and associate Justine K. Glubis. Partner Howard Shelanski and special adviser – EU antitrust Frances Dethmers are providing antitrust and competition advice. Partner Michael Mollerus is providing tax advice. Partner David R. Bauer and counsel Samantha Lefland are providing intellectual property advice. Partner Veronica M. Wissel and counsel Joseph S. Brown are providing executive compensation advice. Members of the Davis Polk team are based in the New York, Washington DC and Brussels offices.

Copy link to share post